Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

39.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.8K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Dementia01:30

Dementia

165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
165
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis.

Molecular neurodegeneration·2026
Same author

Agreement between bioimpedance-measured and calf-derived appendicular skeletal muscle mass in amyotrophic lateral sclerosis patients.

European journal of clinical nutrition·2026
Same author

Sex-Specific Genetic Architecture of ALS: Evidence of a Female Protective Effect?

Annals of neurology·2026
Same author

Ecological momentary assessments for patients with hereditary angioedema: a feasibility and acceptability controlled study.

Frontiers in digital health·2026
Same author

Development and validation of predictive models for 6-month gastrostomy timing in amyotrophic lateral sclerosis.

BMJ neurology open·2026
Same author

Correction to: Telephone-based cognitive screening in neurodegenerative MCI and dementia: preliminary findings from the TBCS Study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026

Related Experiment Video

Updated: Sep 8, 2025

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.2K

A verb-naming test accurately detects cognitive changes in ALS.

Edoardo Nicolò Aiello1, Debora Pain2, Alice Radici2

  • 1PhD Program in Neuroscience, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|June 15, 2022
PubMed
Summary
This summary is machine-generated.

Verb naming tests accurately detect cognitive impairment in Amyotrophic Lateral Sclerosis (ALS) patients. The Action-Verb-Naming Test (AVNT) shows high accuracy and sensitivity in identifying these changes, aiding in early diagnosis.

Keywords:
Amyotrophic lateral sclerosisbiomarkerdementiaepidemiologyfrontotemporal degenerationlanguage impairmentverb naming

More Related Videos

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

34.9K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

27.1K

Related Experiment Videos

Last Updated: Sep 8, 2025

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.2K
A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

34.9K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

27.1K

Area of Science:

  • Neurology
  • Cognitive Neuroscience

Background:

  • Cognitive impairment is common in Amyotrophic Lateral Sclerosis (ALS).
  • Verb-naming tests are proposed for detecting cognitive changes, but clinical evidence is limited.
  • The Action-Verb-Naming Test (AVNT) assesses the ability to name actions.

Purpose of the Study:

  • To evaluate the clinical usefulness of the AVNT in detecting cognitive impairment in ALS patients.
  • To assess the diagnostic accuracy of the AVNT in distinguishing ALS patients from healthy controls.
  • To determine the association between AVNT performance and other cognitive measures in ALS.

Main Methods:

  • 29 ALS patients and 29 healthy controls (HCs) were recruited.
  • Participants completed the Action-Verb-Naming Test (AVNT).
  • ALS patients also underwent the Edinburgh Cognitive and Behavioral ALS Screen (ECAS) and were classified using established criteria.

Main Results:

  • The AVNT effectively discriminated between ALS patients and HCs (p=0.026).
  • The AVNT demonstrated high accuracy (88%) in detecting cognitive impairments in ALS patients (sensitivity=1, specificity=0.84).
  • AVNT performance was strongly associated with ECAS scores (r=0.65-0.75) but not other clinical variables.

Conclusions:

  • Verb naming, as assessed by the AVNT, is an accurate method for detecting domain-specific cognitive changes in ALS.
  • The AVNT can identify cognitive deficits irrespective of the ALS disease phenotype.
  • This study provides statistical evidence supporting the clinical utility of verb-naming tests in ALS cognitive assessment.